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simple risk model could aid in decision-making in the clinic
and highlights areas of potential intervention to reduce NRM
following auto HCT.
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Introduction: Survivors after HCT often have musculoskel-
etal complications and symptoms. Although risk factors for
many of the musculoskeletal complications have been
deﬁned, risk factors for symptoms remain unknown.
Methods: All HCT survivors treated at the Fred Hutchinson
Cancer Research Center and living in zip codes beginning with
98 were approached and asked to complete patient reported
outcomes (PRO) and permit use of their medical records. To
reduce age-related confounding ofmusculoskeletal symptoms
associated with HCT, eligibility criteria included survivors
between ages 18-49, with myeloablative HCT for hematologic
malignancy between 5-20 years before approach and English
proﬁciency adequate to complete the PRO. Exclusion criteria
were relapse or second cancer other than basal or squamous
cell skin cancer within the previous 2 years. We used the
Muscle and Joint Measure (MJM) with subscales to evaluate
outcomes of cramps, arthralgias, myalgias and weakness. Due
to a lack of normative information, we used the mean plus 0.5
SD for each subscale as a cut point to deﬁnepatientswithmore
severe symptoms. Variables signiﬁcant at p<.10 were retained
from univariate regressions, followed by backward elimina-
tion to p<.05 level for the ﬁnal models.
Results: Of 170 eligible participants, 142 completed the PRO
(84%). A majority were male (53%) with mean age 39.5
(SD¼8.9), years post-HCT mean of 11.2 (SD¼4.6); 40%
received related allogeneic HCT, 32% unrelated, 28% autolo-
gous; 65% received TBI, 32% received bone marrow as aTable 1
Final models for multivariate logistic regressions of risk factors for
musculoskeletal symptoms
OR (95% CI) P
Cramps
Age  40 2.45 (1.1-5.5) 0.03
Katz comorbidity  2 2.42 (1.1-5.3) 0.03
Arthritis 6.71 (2.4-18.5) 0.0002
AVN 3.28 (1.2-8.8) 0.02
Arthralgia
GVHD meds now 8.68 (2.1-35.5) 0.003
Age  40 4.44 (1.6-12.2) 0.004
Arthritis 22.3 (6.9-72.7) <0.0001
Myalgia
Katz comorbidity  2 2.27 (1.1-4.8) 0.03
AVN 2.83 (1.1-7.1) 0.03
Weakness
GVHD meds now 12.4 (2.4-63.0) 0.002
AVN 3.09 (1.1-8.4) 0.03
Diabetes 6.71 (1.8-25.2) 0.005source of stem cells. For late effects potentially relevant to
musculoskeletal symptoms, 16% had taken oral immuno-
suppressants for >24 months for chronic graft versus host
disease (cGVHD), 8% were currently taking medication for
cGVHD, 8% were taking diabetes medication, 17% reported
avascular necrosis (AVN), 18% reported arthritis, and 49% had
 2 comorbid conditions. Survivors reporting symptoms of
moderate or greater intensity (>4 on 0-10 scale) and occur-
ring at least weekly were: cramps 30%, myalgias 26%, joints
22%, and weakness 20%. Table 1 deﬁnes risk factors.
Conclusions: Different risk factors predicted each of the
musculoskeletal symptoms in HCT survivors. Further
research is needed to understand mechanisms and treat-
ments for these symptoms, particularly for cramps which are
the most prevalent.LEUKEMIA
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Introduction: Central nervous system (CNS) involvement
in adult acute myeloid leukemia (AML) occurs in 2-4% of
patients at diagnosis, and is considered to have a poor
prognosis. Therefore, CNS involvement in AML is an indi-
cator for allogeneic hematopoietic stem cell transplantation
(allo-HSCT). However, the impact of CNS involvement in
AML on the outcome of allo-HSCT remains unclear. We
performed a large-scale nationwide retrospective analysis
to elucidate the outcomes of allo-HSCT for AML with CNS
involvement.
Methods: Clinical data were collected from a registry
database of the Japan Society for Hematopoietic Cell Trans-
plantation. AML patients with CNS involvement aged
16 years or older who underwent the ﬁrst allo-HSCT between
January 2006 and December 2011were compared to the AML
patients without CNS involvement who underwent the ﬁrst
allo-HSCT in the same period. CNS diseases of these patients
were diagnosed at any time from onset to allo-HSCT. The
clinical factors affecting overall survival (OS) of AML patients
with CNS involvement were analyzed using log-rank test and
Cox proportional hazard model.
Result: There were 157 and 4911 AML patients with
and without CNS involvement, respectively. Clinical
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involvement are as follows median age 45 (17-68) vs. 50
(16-82) (p¼0.0004), Disease status(standard/high
risk):63(40%)/94(60%) vs. 2361(48%)/2549(52%) (p¼0.0044).
The estimated OS, cumulative incidence (CI) of relapse and
non-relapse mortality in AML with CNS involvement were
comparable to those for AML without CNS involvement
(5-year OS, CI of relapse and NRM of AML with and without
CNS involvement was 38.5% vs. 39.9% (p¼0.847), 31.8% vs.
29.8% (p¼0.418) and 26.7% vs. 29.0%(p¼0.278) respectively).
Univariate analysis showed that age at allo-HSCT (older than
50 years), the absence of chronic graft versus host disease
(cGVHD), high risk of disease status (>¼3rdcomplete
response (CR3)/non-CR), worse ECOG performance status
(>¼2) and poor cytogenetic risk category according to
SWOG deﬁnition predicted worse OS in AML with CNS
involvement. Multivariate analysis showed that the devel-
opment of cGVHD, disease status and cytogenetic risk
category are independent prognostic factors for OS.
Conclusion: The current study showed that the outcomes of
allo-HSCT for AML with CNS involvement were comparable
to those of AML without CNS involvement. These results
suggest that allo-HSCT may overcome the poor prognosis of
AML with CNS involvement and should be an effective
therapeutic option for these patients.69
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Survivin is broadly expressed by hematological malig-
nancies and may be a suitable target for T-cell immuno-
therapy. Previously, the utility of this approach has been
challenged by the occurrence of “fratricide” when T cells
expressing a high avidity survivin-speciﬁc T cell receptor
(TCR) isolated from allogeneic cultures killed each other
because survivin epitopes can be presented by T cells
themselves (Leisegang M et al, J Clin Invest. 2010;120:3869).
To overcome this obstacle, we used autologous cultures to
isolate a new T-cell clone targeting the HLA-A*02-restricted
survivin95-104 epitope. This clone displayed nanomolar
avidity and speciﬁc killing against survivin+HLA-A*02+ leu-
kemia cells (BV173, 3916% speciﬁc lysis, E:T 40:1) and
multiple myeloma cells (U266, 207%) but not against HLA-
A*02e HL-60 cells (22%). Colony formation of primary
myeloid leukemias was inhibited (>50% reduction) while
that of healthy bone marrow (BM) was not. The TCR a- and
b-chains were cloned in a retroviral vector and used to
efﬁciently transduce CD8+ T cells (894%, n¼6). As
compared to non-transduced (NT) T cells, TCR+ T cells pro-
duced signiﬁcant lysis of BV173 (4614% vs 86%, E:T 20:1,
n¼12, p<0.001) and U266 (2712% vs 146%, p¼0.003) but
not of HL-60 (147 vs 146 %, p¼NS). TCR+ cells also
inhibited colony formation (32-78% reduction, n¼5) of pri-
mary myeloid leukemias while preserving normal clono-
genic capacity of BM or CB (n¼5). When tested in vivo in a
xenograft mouse model of leukemia (FFLuc+BV173) with
bioluminescent imaging, progression was signiﬁcantly
slower in mice treated with TCR+ versus NT T cells (8.1x106
 9x106 vs 195x106  85x106 photons/sec) (day 40,
p¼0.003, n¼10/group). Overall survival was improved (day80, p<0.001) and 3/10 mice treated with TCR+ T cells
completely cleared the leukemia. Crucially, the TCR cloned
from our autologous culture system produced no fratricidal
activity against HLA-A*02+ activated T cells (12%, E:T 20:1,
n¼7). To elucidate at the molecular level the selective
antitumor activity of our “autologous” TCR as opposed to
the fratricidal “allogeneic” TCRs, we modeled the structure
of each TCR-peptide-HLA ternary complex. While the overall
binding energies of TCR-peptide-HLA interfaces for both
TCRs were similar, the “autologous” TCR showed a 48%
higher binding energy contribution for the peptide as
compared to the fratricidal TCR, whose interaction was
primarily with the HLA molecule rather than with the sur-
vivin peptide in the HLA-binding groove. In conclusion, we
have cloned a novel survivin-TCR with a highly epitope-
speciﬁc binding mode that can be efﬁciently expressed in
polyclonal T cells and provides antitumor activity in vitro
and in vivowithout affecting the survival of T cells or normal
hematopoiesis. Our results indicate that maximal recogni-
tion of the peptide presented in the HLA groove is critical
for TCR selectivity.70
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Introduction: Extra-medullary (EM) leukemia is present in 3
e 8% of persons with AML. Although controversial, retro-
spective analyses have suggested an adverse impact on
outcomes of conventional therapy. Although use of allo-
transplants might overcome this adverse prognostic impact,
data supporting this approach are limited. Isolated EM
relapses occur after allotransplants and may reﬂect lack of
graft vs leukemia effect in EM sites. Also, the use of reduced-
intensity conditioning (RIC) regimens, T-cell-depleted grafts
and non-radiation-based conditioning regimens may be
associated with higher rates of EM relapse and similarly may
reduce the effectiveness of allotransplants in persons with
AML and EM leukemia.
Methods: Retrospective analysis of variables associated with
outcome of allotransplants for persons with AML with or
without EM leukemia pretransplant was performed. The
study population included subjects age 18-70 receiving
HLA-identical sibling or HLA-matched unrelated donor
transplants of bonemarrowor cells from1995-2010 reported
to the CIBMTR.
Results: 9797 subjects met the selection criteria, 814 (8%) of
whom had extra-medullary leukemia at different times
pretransplant. Median follow-up of survivors was 58 mo
(range, 3-191 mo) for subjects with EM leukemia and 60 mo
(range, 3-194 mo) for patients without EM leukemia.
Univariate analysis of outcomes showed no difference in
leukemia-free survival (LFS) or survival of subjects with or
without EM leukemia pretransplant. 5 y LFSs were 33% (95%
